NCT06991634View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of Azvudine Tablets in Healthy Adult Subjects and Healthy Elderly Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2023

Primary Completion Date

April 27, 2023

Study Completion Date

June 20, 2023

Conditions

Healthy

Interventions

DRUG

Azvudine tablets

"Phase I: oral administration of 5 mg of Azvudine tablets on an empty stomach, single dose, 5 tablets per dose.~Phase II: oral administration of 5 mg of Azvudine tablets once a day on an empty stomach, 5 tablets once a day, for 7 consecutive days."

Trial Locations (1)

Unknown

Tianjin Fifth Central Hospital, Tianjin

All Listed Sponsors

lead

Henan Genuine Biotech Co., Ltd.

INDUSTRY